Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics

References

• ShuldinerARO’ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302884985719706858
   PubMed Web of Science ®Google Scholar
• FaradayNYanekLRMathiasRHeritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1Circulation2007115192490249617470694
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityCirculation2003107232908291312796140
   PubMed Web of Science ®Google Scholar
• GurbelPACummingsCCBellCRAlfordABMeisterAFSerebruanyVLPlavix Reduction Of New Thrombus Occurrence (PRONTO) trial.Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trialAm Heart J2003145223924712595840
   PubMed Web of Science ®Google Scholar
• SerebruanyVLSteinhublSRBergerPBMalininAIBhattDLTopolEJVariability in platelet responsiveness to clopidogrel among 544 individualsJ Am Coll Cardiol200545224625115653023
   PubMed Web of Science ®Google Scholar
• BonelloLTantryUSMarcucciRWorking Group on High On-Treatment Platelet ReactivityConsensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphateJ Am Coll Cardiol2010561291993320828644
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdBhattDLLeeRDClopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionJ Am Coll Cardiol201361887287923333143
   PubMed Web of Science ®Google Scholar
• AmeyawMMRegateiroFLiTMDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicityPharmacogenetics200111321722111337937
   PubMedGoogle Scholar
• TaubertDvon BeckerathNGrimbergGImpact of P-glycoprotein on clopidogrel absorptionClin Pharmacol Ther200680548650117112805
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMFrench Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) InvestigatorsGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDGenetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisLancet201037697491312131920801494
   PubMed Web of Science ®Google Scholar
• LuoMLiJXuXSunXShengWABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysisThromb Res2012129675475922209339
   PubMed Web of Science ®Google Scholar
• SuJXuJLiXABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysisPLoS One2012710e4636623056288
   PubMed Web of Science ®Google Scholar
• KazuiMNishiyaYIshizukaTIdentification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metaboliteDrug Metab Dispos2010381929919812348
   PubMed Web of Science ®Google Scholar
• de MoraisSMWilkinsonGRBlaisdellJNakamuraKMeyerUAGoldsteinJAThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansJ Biol Chem19942692215419154228195181
   PubMed Web of Science ®Google Scholar
• SimSCRisingerCDahlMLA common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther200679110311316413245
   PubMed Web of Science ®Google Scholar
• HulotJSBuraAVillardECytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjectsBlood200610872244224716772608
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• KimKAParkPWHongSJParkJYThe effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistanceClin Pharmacol Ther200884223624218323861
   PubMed Web of Science ®Google Scholar
• VarenhorstCJamesSErlingeDGenetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEur Heart J200930141744175219429918
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSAnzahaGCLOVIS-2 InvestigatorsHigh doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)JACC Cardiovasc Interv20114439240221511218
   PubMed Web of Science ®Google Scholar
• HulotJSColletJPCaylaGCYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsCirc Cardiovasc Interv20114542242821972404
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKSteinCMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 updateClin Pharmacol Ther201394331732323698643
   PubMed Web of Science ®Google Scholar
• O’ConnorSAHulotJSSilvainJCaylaGMontalescotGColletJPPharmacogenetics of clopidogrelCurr Pharm Des201218335309532722724417
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• ColletJPHulotJSPenaACytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyLancet2009373966030931719108880
   PubMed Web of Science ®Google Scholar
• SibbingDStegherrJLatzWCytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEur Heart J200930891692219193675
   PubMed Web of Science ®Google Scholar
• ParéGMehtaSRYusufSEffects of CYP2C19 genotype on outcomes of clopidogrel treatmentN Engl J Med2010363181704171420979470
   PubMed Web of Science ®Google Scholar
• HulotJSColletJPSilvainJCardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysisJ Am Coll Cardiol201056213414320620727
   PubMed Web of Science ®Google Scholar
• MegaJLSimonTColletJPReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysisJAMA2010304161821183020978260
   PubMed Web of Science ®Google Scholar
• SofiFGiustiBMarcucciRGoriAMAbbateRGensiniGFCytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysisPharmacogenomics J201111319920620351750
   PubMed Web of Science ®Google Scholar
• BauerTBoumanHJvan WerkumJWFordNFten BergJMTaubertDImpact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisBMJ2011343d458821816733
   PubMed Web of Science ®Google Scholar
• ZabalzaMSubiranaISalaJMeta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrelHeart201298210010821693476
   PubMed Web of Science ®Google Scholar
• JohnsonJACavallariLHPharmacogenetics and cardiovascular disease – implications for personalized medicinePharmacol Rev2013653987100923686351
   PubMed Web of Science ®Google Scholar
• HolmesMVPerelPShahTHingoraniADCasasJPCYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysisJAMA2011306242704271422203539
   PubMed Web of Science ®Google Scholar
• ShuldinerARVeselyMRFischACYP2C19 genotype and cardiovascular eventsJAMA2012307141482 ; author reply 1484–1485.22496255
   PubMed Web of Science ®Google Scholar
• MegaJLTopolEJSabatineMSCYP2C19 genotype and cardiovascular eventsJAMA20123071414821483 ; author reply 1484–1485.22496256
   PubMed Web of Science ®Google Scholar
• FréreCCuissetTGaboritBAlessiMCHulotJSThe CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndromeJ Thromb Haemost2009781409141119496924
   PubMed Web of Science ®Google Scholar
• LewisJPStephensSHHorensteinRBThe CYP2C19*17 variant is not independently associated with clopidogrel responseJ Thromb Haemost20131191640164623809542
   PubMed Web of Science ®Google Scholar
• LiYTangHLHuYFXieHGThe gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patientsJ Thromb Haemost201210219920622123356
   PubMed Web of Science ®Google Scholar
• BoumanHJSchomigEvan WerkumJWParaoxonase-1 is a major determinant of clopidogrel efficacyNat Med201117111011621170047
   PubMed Web of Science ®Google Scholar
• LewisJPFischASRyanKParaoxonase 1 (PON1) gene variants are not associated with clopidogrel responseClin Pharmacol Ther201190456857421881565
   PubMed Web of Science ®Google Scholar
• RenyJLCombescureCDaaliYFontanaPPON1 Meta-Analysis GroupInfluence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysisJ Thromb Haemost20121071242125122520065
   PubMed Web of Science ®Google Scholar
• LiXZhangLChenXPON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivityThromb Res2013132444444923993903
   PubMed Web of Science ®Google Scholar
• ParkKWParkJJKangJParaoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCIPLoS One201382e5277923418418
   PubMed Web of Science ®Google Scholar
• LewisJPHorensteinRBRyanKThe functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responsePharmacogenet Genomics20132311823111421
   PubMed Web of Science ®Google Scholar
• ZhuHJWangXGawronskiBEBrindaBJAngiolilloDJMarkowitzJSCarboxylesterase 1 as a determinant of clopidogrel metabolism and activationJ Pharmacol Exp Ther2013344366567223275066
   PubMed Web of Science ®Google Scholar
• HarmszeAvan WerkumJWBoumanHJBesides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantationPharmacogenet Genomics2010201182519934793
   PubMed Web of Science ®Google Scholar
• ParkKWParkJJJeonKHEnhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 statusArterioscler Thromb Vasc Biol201131366567121148426
   PubMed Web of Science ®Google Scholar
• FischASPerryCGStephensSHHorensteinRBShuldinerARPharmacogenomics of anti-platelet and anti-coagulation therapyCurr Cardiol Rep201315738123797323
   PubMed Web of Science ®Google Scholar
• BuraABachelot-LozaCAliFDAiachMGaussemPRole of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjectsJ Thromb Haemost2006492096209716961627
   PubMed Web of Science ®Google Scholar
• CaylaGHulotJSO’ConnorSAClinical, angiographic, and genetic factors associated with early coronary stent thrombosisJAMA2011306161765177422028352
   PubMed Web of Science ®Google Scholar
• LevEIPatelRTGuthikondaSLopezDBrayPFKleimanNSGenetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrelThromb Res2007119335536016581111
   PubMed Web of Science ®Google Scholar
• MansourKTaherATMusallamKMAlamSAspirin resistanceAdv Hematol2009200993735219960045
   PubMedGoogle Scholar
• BeckerDMSegalJVaidyaDSex differences in platelet reactivity and response to low-dose aspirin therapyJAMA2006295121420142716551714
   PubMed Web of Science ®Google Scholar
• GrosserTFriesSLawsonJAKapoorSCGrantGRFitzGeraldGADrug resistance and pseudoresistance: an unintended consequence of enteric coating aspirinCirculation2013127337738523212718
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPDiChiaraJEvaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) studyCirculation2007115253156316417562955
   PubMed Web of Science ®Google Scholar
• VooraDOrtelTLLucasJEChiJTBeckerRCGinsburgGSTime-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapyJ Thromb Thrombolysis201233324625722294277
   PubMed Web of Science ®Google Scholar
• ShenHHerzogWDroletMAspirin resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study)Am J Cardiol2009104460661219660620
   PubMed Web of Science ®Google Scholar
• FrelingerAL3rdLiYLindenMDAssociation of cycloox-ygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterizationCirculation2009120252586259619996015
   PubMed Web of Science ®Google Scholar
• SnoepJDHovensMMEikenboomJCvan der BomJGHuismanMVAssociation of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysisArch Intern Med2007167151593159917698681
   PubMedGoogle Scholar
• BenedekIHJoshiASPieniaszekHJKingSYKornhauserDMVariability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteersJ Clin Pharmacol19953512118111868750369
   PubMed Web of Science ®Google Scholar
• ZhouGMaratheGKHartialaJAspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2)J Biol Chem201328817119401194823508960
   PubMed Web of Science ®Google Scholar
• ZhouGMaratheGKWillardBMcIntyreTMIntracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in bloodJ Biol Chem201128640348203482921844189
   PubMed Web of Science ®Google Scholar
• ZimmermannNWenkAKimUFunctional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgeryCirculation2003108554254712874188
   PubMed Web of Science ®Google Scholar
• MattielloTGuerrieroRLottiLVAspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass graftingJ Am Coll Cardiol201158775276121816313
   PubMed Web of Science ®Google Scholar
• LepäntaloAMikkelssonJReséndizJCPolymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patientsThromb Haemost200695225325916493486
   PubMed Web of Science ®Google Scholar
• SmithSMJudgeHMPetersGPAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapyPlatelets200516634034516194864
   PubMed Web of Science ®Google Scholar
• HerreraJEQayyumRFaradayNAbstract 1440: platelet response to aspirin is under polygenic control of variants in the VAV3 and phospholipase C gamma 2 (PLCG2) genesCirculation2008118S_326
   Web of Science ®Google Scholar
• Herrera-GaleanoJEBeckerDMWilsonAFA novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregabilityArterioscler Thromb Vasc Biol20082881484149018511696
   PubMed Web of Science ®Google Scholar
• UndasABrummelKMusialJMannKGSzczeklikAPl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injuryCirculation2001104222666267211723016
   PubMed Web of Science ®Google Scholar
• CookeGEBrayPFHamlingtonJDPhamDMGoldschmidt-ClermontPJPlA2 polymorphism and efficacy of aspirinLancet19983519111125312539643753
   PubMed Web of Science ®Google Scholar
• CookeGELiu-StrattonYFerketichAKEffect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combinationJ Am Coll Cardiol200647354154616458133
   PubMed Web of Science ®Google Scholar
• JohnsonADYanekLRChenMHGenome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonistsNat Genet201042760861320526338
   PubMed Web of Science ®Google Scholar
• FaradayNYanekLRYangXPIdentification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expressionBlood2011118123367337521791418
   PubMed Web of Science ®Google Scholar
• LewisJPRyanKO’ConnellJRGenetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomesCirc Cardiovasc Genet20136218419223392654
   PubMed Web of Science ®Google Scholar
• KauskotAVandenbrieleCLouwetteSPEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathwayBlood2013121265208521723667054
   PubMed Web of Science ®Google Scholar
• KauskotADi MicheleMLoyenSFresonKVerhammePHoylaertsMFA novel mechanism of sustained platelet alphaIIbbeta3 activation via PEAR1Blood2012119174056406522371881
   PubMed Web of Science ®Google Scholar
• VooraDCyrDLucasJAspirin exposure reveals novel genes associated with platelet function and cardiovascular eventsJ Am Coll Cardiol201362141267127623831034
   PubMed Web of Science ®Google Scholar
• VooraDHortonJShahSHShawLKNewbyLKPolymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin useAm Heart J20111621166172 e161.21742104
   PubMed Web of Science ®Google Scholar
• Le HelloCMorelloRLequerrecADuarteCRiddellJHamonMEffect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stentingThromb J200751918021403
   PubMedGoogle Scholar
• ClarkRPedenJFHopewellJCPROCARDIS ConsortiumGenetic variants associated with Lp(a) lipoprotein level and coronary diseaseN Engl J Med2009361262518252820032323
   PubMed Web of Science ®Google Scholar
• ChasmanDIShiffmanDZeeRYPolymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapyAtherosclerosis2009203237137618775538
   PubMed Web of Science ®Google Scholar
• ThomasGSVorosSMcPhersonJAA blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS StudyCirc Cardiovasc Genet20136215416223418288
   PubMedGoogle Scholar
• AngiolilloDJBhattDLGurbelPAJenningsLKAdvances in antiplatelet therapy: agents in clinical developmentAm J Cardiol2009103Suppl 340A51A
   Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J2008291213018055486
   PubMed Web of Science ®Google Scholar
• PayneCDLiYGSmallDSIncreased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelJ Cardiovasc Pharmacol200750555556218030066
   PubMed Web of Science ®Google Scholar
• TengRMayaJButlerKEvaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteersPlatelets201324861562423249161
   PubMed Web of Science ®Google Scholar
• HustedSEStoreyRFBlidenKPharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studiesClin Pharmacokinet201251639740922515556
   PubMed Web of Science ®Google Scholar
• NylanderSFemiaEAScavoneMTicagrelor inhibits human platelet aggregation via adenosine in addition to P2Y antagonismJ Thromb Haemost201311101867187623890048
   PubMed Web of Science ®Google Scholar
• BonelloLPansieriMManciniJHigh on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromesJ Am Coll Cardiol201158546747321777742
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation2009119192553256019414633
   PubMed Web of Science ®Google Scholar
• FrankenCCKaiserAFKrügerJCOverbeckKMüggeANeubauerHCytochrome P450 2B6 and 2C9 genotype polymorphism – a possible cause of prasugrel low responsivenessThrom Haemost20131101131140
   Web of Science ®Google Scholar
• CuissetTLoosveldMMorangePECYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndromeJACC Cardiovasc Interv20125121280128723257377
   PubMed Web of Science ®Google Scholar
• XiangQCuiYZhaoXZhaoNIdentification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamicsPharmacogenomics201314101179118923859572
   PubMed Web of Science ®Google Scholar
• TantryUSBlidenKPWeiCFirst analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studiesCirc Cardiovasc Genet20103655656621079055
   PubMed Web of Science ®Google Scholar
• WallentinLJamesSStoreyRFPLATO investigatorsEffect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialLancet201037697491320132820801498
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesNew Engl J Med20093611045105719717846
   PubMed Web of Science ®Google Scholar
• VarenhorstCErikssonNJohanssonÅTicagrelor plasma levels but not clinical outcomes are associated with transporter and metabolism enzyme genetic polymorphismsJ Am Coll Cardiol20146312_S
   Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics CKleinTEAltmanRBEstimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med2009360875376419228618
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• PirmohamedMJamesSMeakinSAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ20043297456151915231615
   PubMed Web of Science ®Google Scholar
• FungEPatsopoulosNABelknapSMEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinSemin Thromb Hemost201238889390423041981
   PubMed Web of Science ®Google Scholar
• JohnsonJACavallariLHBeitelsheesALLewisJPShuldinerARRodenDMPharmacogenomics: application to the management of cardiovascular diseaseClin Pharmacol Ther201190451953121918509
   PubMed Web of Science ®Google Scholar
• LeeMTKleinTEPharmacogenetics of warfarin: challenges and opportunitiesJ Hum Genet201358633433823657428
   PubMed Web of Science ®Google Scholar
• JorgensenALFitzGeraldRJOyeeJPirmohamedMWilliamsonPRInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisPloS One201278e4406422952875
   PubMed Web of Science ®Google Scholar
• CaldwellMDAwadTJohnsonJACYP4F2 genetic variant alters required warfarin doseBlood200811184106411218250228
   PubMed Web of Science ®Google Scholar
• TakeuchiFMcGinnisRBourgeoisSA genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dosePLoS Genet200953e100043319300499
   PubMed Web of Science ®Google Scholar
• PirmohamedMBurnsideGErikssonNEU-PACT GroupA randomized trial of genotype-guided dosing of warfarinN Engl J Med2013369242294230324251363
   PubMed Web of Science ®Google Scholar
• KimmelSEFrenchBKasnerSECOAG InvestigatorsA pharmacogenetic versus a clinical algorithm for warfarin dosingN Engl J Med2013369242283229324251361
   PubMed Web of Science ®Google Scholar
• VerhoefTIRagiaGde BoerAEU-PACT GroupA randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumonN Engl J Med2013369242304231224251360
   PubMed Web of Science ®Google Scholar
• KirchheinerJUferMWalterECEffects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteersPharmacogenetics2004141192615128047
   PubMedGoogle Scholar
• SchalekampTOosterhofMvan MeegenEEffects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation statusClin Pharmacol Ther200476540941715536456
   PubMed Web of Science ®Google Scholar
• TeichertMEijgelsheimMUitterlindenAGDependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genesPharmacogenet Genomics2011211263421063236
   PubMed Web of Science ®Google Scholar
• CavallariLHPereraMAThe future of warfarin pharmacogenetics in under-represented minority groupsFuture Cardiol20128456357622871196
   PubMedGoogle Scholar
• PereraMACavallariLHLimdiNAGenetic variants associated with warfarin dose in African-American individuals: a genome-wide association studyLancet2013382989479079623755828
   PubMed Web of Science ®Google Scholar
• ParéGErikssonNLehrTGenetic determinants of dabigatran plasma levels and their relation to bleedingCirculation2013127131404141223467860
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PirmohamedMBurnsideGErikssonNEU-PACT GroupA randomized trial of genotype-guided dosing of warfarinNew Engl J Med20133692294230324251363
   PubMed Web of Science ®Google Scholar
• KimmelSEFrenchBKasnerSECOAG InvestigatorsA pharmacogenetic versus a clinical algorithm for warfarin dosingNew Engl J Med2013369242283229324251361
   PubMed Web of Science ®Google Scholar
• RobertsJDWellsGALe MayMRPoint-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trialLancet201237998271705171122464343
   PubMed Web of Science ®Google Scholar
• XieXMaYTYangYNPersonalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trialInt J Cardiol201316843736374023850318
   PubMed Web of Science ®Google Scholar
• JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
   PubMed Web of Science ®Google Scholar
• KaziDSGarberAMShahRUCost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndromeAnn Intern Med2014160422123224727840
   PubMed Web of Science ®Google Scholar
• LalaABergerJSSharmaGHochmanJSScott BraithwaiteRLadapoJAGenetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysisJ Thromb Haemost2013111819123137413
   PubMed Web of Science ®Google Scholar
• ReeseESDaniel MullinsCBeitelsheesALOnukwughaECost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrelPharmacotherapy201232432333222461122
   PubMed Web of Science ®Google Scholar
• SorichMJHorowitzJDSorichWWieseMDPekarskyBKarnonJDCost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in AustraliaPharmacogenomics201314162013202124279856
   PubMed Web of Science ®Google Scholar
• PinkJPirmohamedMLaneSHughesDACost-effectiveness of pharmacogenetics-guided warfarin therapy vs alternative anticoagulation in atrial fibrillationClin Pharmacol Ther201495219920724067746
   PubMed Web of Science ®Google Scholar
• VerhoefTIRedekopWKVeenstraDLEU-PACT GroupCost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillationPharmacogenomics201314886988323746182
   PubMed Web of Science ®Google Scholar
• YouJHPharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysisPharmacogenet Genomics201424161424168919
   PubMed Web of Science ®Google Scholar
• YouJHTsuiKKWongRSChengGCost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillationPloS One201276e3964022745801
   PubMed Web of Science ®Google Scholar
• LeeyJAMcCabeSKochJAMilesTPCost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillationAm J Geriatr Pharmacother20097419720319766951
   PubMed Web of Science ®Google Scholar
• PatrickARAvornJChoudhryNKCost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillationCirc Cardiovasc Qual Outcomes20092542943620031873
   PubMed Web of Science ®Google Scholar
• EckmanMHRosandJGreenbergSMGageBFCost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillationAnn Intern Med20091502738319153410
   PubMed Web of Science ®Google Scholar
• YouJHTsuiKKWongRSChengGPotential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapyClin Pharmacol Ther200986554054719571807
   PubMed Web of Science ®Google Scholar
• SangkuhlKKleinTEAltmanRBClopidogrel pathway. Pharmacogenetics and genomics [webpage on the Internet]PharmGKB2010 Available from: http://www.pharmgkb.org/pathway/PA154424674Accessed May 7, 2014
   Google Scholar